Cargando…

Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

IMPORTANCE: Biosimilar drugs are potentially lower-cost versions of biologics that may improve access to therapy. However, there is a lack of adequate systematic reviews demonstrating equivalence between these drugs for the treatment of rheumatoid arthritis (RA). OBJECTIVES: To assess the efficacy,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascef, Bruna de Oliveira, Almeida, Matheus Oliveira, de Medeiros-Ribeiro, Ana Cristina, Oliveira de Andrade, Danieli Castro, de Oliveira Junior, Haliton Alves, de Soárez, Patrícia Coelho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220520/ https://www.ncbi.nlm.nih.gov/pubmed/37234004 http://dx.doi.org/10.1001/jamanetworkopen.2023.15872

Ejemplares similares

Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis
por: de Oliveira Ascef, Bruna, et al.
Publicado: (2023)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
por: Ascef, Bruna O., et al.
Publicado: (2021)

Health technology assessment of biosimilars worldwide: a scoping review
por: Ascef, Bruna de Oliveira, et al.
Publicado: (2020)

Forecasting models for leprosy cases: a scoping review protocol
por: Oliveira Ascef, Bruna, et al.
Publicado: (2022)

Clinical Equivalence between Generic Versus Branded Antibiotics: Systematic Review and Meta-Analysis
por: Cotia, André, et al.
Publicado: (2023)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Mapping the characteristics, concepts and methodologies of matching-adjusted indirect comparison studies assessing pharmacological therapies in oncology: a scoping review protocol
por: Farinasso, Cecília Menezes, et al.
Publicado: (2023)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Reactivation of cutaneous and mucocutaneous tegumentary leishmaniasis in rheumatoid arthritis patients: an emerging problem?
por: de Souza, Regina Maia, et al.
Publicado: (2017)

Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis
por: Oude Voshaar, Martijn A. H., et al.
Publicado: (2019)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
por: Cohen, Stanley B, et al.
Publicado: (2023)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020)

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
por: Hu, Rui, et al.
Publicado: (2023)

Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab
por: Łosińska, Katarzyna, et al.
Publicado: (2023)

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis
por: Kameda, Hideto, et al.
Publicado: (2020)

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
por: Cohen, Stanley B, et al.
Publicado: (2018)

Access to medicines by patients of the primary health care in the Brazilian Unified Health System
por: Álvares, Juliana, et al.
Publicado: (2017)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

Determining reference ranges for immunological cells of healthy indigenous individuals from a region in Brazil
por: de Morais, Isa Rita Brito, et al.
Publicado: (2023)

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
por: Cohen, Stanley, et al.
Publicado: (2017)

Fibroblast-Like Synoviocytes Glucose Metabolism as a Therapeutic Target in Rheumatoid Arthritis
por: de Oliveira, Patricia Gnieslaw, et al.
Publicado: (2019)

Laryngotracheal separation in pediatric patients: 13-year experience in a reference service
por: Antunes, Letícia Alves, et al.
Publicado: (2019)

Benefits of Home-Based Exercise Training Following Critical SARS-CoV-2 Infection: A Case Report
por: Longobardi, Igor, et al.
Publicado: (2022)

Aging: Molecular Pathways and Implications on the Cardiovascular System
por: de Almeida, Arthur José Pontes Oliveira, et al.
Publicado: (2017)

Switching of biological therapies in Brazilian patients with rheumatoid arthritis
por: de Lucena Valim, Juliana Miranda, et al.
Publicado: (2018)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Health Technology Assessment: informed by science or in the service of politics?
por: de Soárez, Patrícia Coelho
Publicado: (2021)

Different words for stroke: the same concept? an analysis of associated symptoms and intended reaction in Brazil
por: de Mélo Silva Júnior, Mário Luciano, et al.
Publicado: (2023)

Hydroxychloroquine for the management of chronic chikungunya arthritis
por: Nogueira, Igor Albuquerque, et al.
Publicado: (2023)

Health-related quality of life of patients of Brazilian primary health care
por: Ascef, Bruna de Oliveira, et al.
Publicado: (2017)

Collagen‐induced arthritis as an animal model of rheumatoid cachexia
por: Alabarse, Paulo V.G., et al.
Publicado: (2018)

Post-finasteride syndrome()()
por: Pereira, Ana Francisca Junqueira Ribeiro, et al.
Publicado: (2020)

The Behaviour of Serum Survivin in Patients With Lupus Nephritis
por: Lisboa, Renata Valente, et al.
Publicado: (2022)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

Sensory Integration for Postural Control in Rheumatoid Arthritis Revealed by Computerized Dynamic Posturography
por: da Silva, Marta Cristina Rodrigues, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e8ru7uje127acjbavrkji5aob0